In order to investigate alternatives against anti-PD-L1 resistance, we employed a peritoneal carcinomatosis model in which the microenvironment and the high tumor burden reduce the efficacy of HCA-EFZP-aPDL1. The gene discussed is CD274; the disease is neoplasm.